1. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial. Issue 1 (January 2022) Authors: Verma, Subodh; Dhingra, Nitish K; Butler, Javed; Anker, Stefan D; Ferreira, Joao Pedro; Filippatos, Gerasimos; Januzzi, James L; Lam, Carolyn S P; Sattar, Naveed; Peil, Barbara; Nordaby, Matias; Brueckmann, Martina; Pocock, Stuart J; Zannad, Faiez; Packer, Milton; Packer, M; Anker, S; Butler, J; ... Journal: Lancet Issue: Volume 10:Issue 1(2022) Page Start: 35 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Prevalence and clinical predictors of inappropriate direct oral anticoagulant dosage in octagenarians with atrial fibrillation. (14th October 2021) Authors: Carbone, A; Santelli, F; Bottino, R; Attena, E; Mazzone, C; Parisi, V; D'Andrea, A; Golino, P; Nigro, G; Russo, V Journal: European heart journal Issue: Volume 42(2021)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗